Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus

Lupus

Volumn 18, Issue 6, 2009, Pages 501-507

  Her, M ^a   Kim, D ^a   Oh, M ^a   Jeong, H ^b   Choi, Inhak ^b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Inducible T cell costimulator ligand; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CD274 ANTIGEN; HYDROXYCHLOROQUINE; INDUCIBLE COSTIMULATOR LIGAND; LYMPHOCYTE ANTIGEN; MESSENGER RNA; PREDNISONE; PROGRAMMED DEATH 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 65149102534     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308099176     Document Type: Article

References (34)

1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
2. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
3. Keir ME, Sharpe AH. The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005; 204: 128-143.
4. Warnatz K, Bossaller L, Salzer U. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006; 107: 3045-3052.
5. Lee WI, Zhu Q, Gambineri E, Jin Y, Welcher AA, Ochs HD. Inducible CO-stimulator molecule, a candidate gene for defective isotype switching, is normal in patients with hyper-IgM syndrome of unknown molecular diagnosis. J Allergy Clin Immunol 2003; 112: 958-964.
6. Beier KC, Hutloff A, Lohning M, Kallinich T, Kroczek RA, Hamelmann E. Inducible costimulator-positive T cells are required for allergen-induced local B-cell infiltration and antigen-specific IgE production in lung tissue. J Allergy Clin Immunol 2004; 114: 775-782.
7. Nurieva RI, Mai XM, Forbush K, Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function. Proc Natl Acad Sci U S A 2003; 100: 14163-14168.
8. Ruth JH, Rottman JB, Kingsbury GA. ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis. Cytometry A 2007; 71: 317-326.
9. Chen YQ, Shi HZ. CD28/CTLA-4-CD80/CD86 and ICOS-B7RP-1 costimulatory pathway in bronchial asthma. Allergy 2006; 61: 15-26.
10. Wiley RE, Goncharova S, Shea T, Johnson JR, Coyle AJ, Jordana M. Evaluation of inducible costimulator/B7-related protein-1 as a therapeutic target in a murine model of allergic airway inflammation. Am J Respir Cell Mol Biol 2003; 28: 722-730.
11. Greenwald RJ, McAdam AJ, Van der Woude D, Satoskar AR, Sharpe AH. Cutting edge: Inducible costimulator protein regulates both Th1 and Th2 responses to cutaneous leishmaniasis. J Immunol 2002; 168: 991-995.
12. Horwitz DA, Stohl W, Gray JD. T lymphocytes, natural killer cells, and immune regulation. In: Wallace, DJ, Hahn, BH (eds), Dubois' lupus erythematosus, 6th ed. Lippincott Williams and Wilkins; 2002. p. 157-186.
13. Dall'Era M, Davis J. CTLA4Ig: A novel inhibitor of costimulation. Lupus 2004; 13: 372-376.
14. Okamoto T, Saito S, Yamanaka H. Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1157-1163.
15. Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus. J Immunol 2000; 165: 3436-3443.
16. Yu D, Tan AH, Hu X. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007; 450: 299-303.
17. Kawamoto M, Harigai M, Hara M. Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: Possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production. Arthritis Res Ther 2006; 8: R62-R62.
18. Tada Y, Koarada S, Tomiyoshi Y. Role of inducible costimulator in the development of lupus in MRL/lpr mice. Clin Immunol 2006; 120: 179-188.
19. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003; 198: 39-50.
20. Wang SC, Lin CH, Li RN. Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis. J Clin Immunol 2007; 27: 563-567.
21. Kobayashi M, Kawano S, Hatachi S. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005; 32: 2156-2163.
22. Ding H, Wu X, Wu J. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol 2006; 118: 258-267.
23. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
25. Hutloff A, Buchner K, Reiter K. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3211-3220.
26. Yang JH, Zhang J, Cai Q. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1245-1254.
27. Coyle AJ, Lehar S, Lloyd C. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13: 95-105.
28. Dong C, Juedes AE, Temann UA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409: 97-101.
29. Katsumata Y, Harigai M, Sugiura T. Attenuation of experimental autoimmune myositis by blocking ICOS-ICOS ligand interaction. J Immunol 2007; 179: 3772-3779.
30. Coyle AJ, Gutierrez-Ramos JC. The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin Immunopathol 2004; 25: 349-359.
31. Iwai H, Abe M, Hirose S. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 2003; 171: 2848-2854.
32. Magistrelli G, Jeanin P, Elson G. Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys Res Commun 1999; 259: 34-37.
33. Logue EC, Bakkour S, Murphy MM, Nolla H, Sha WC. ICOS-induced B7h shedding on B cells is inhibited by TLR7/8 and TLR9. J Immunol 2006; 177: 2356-2364.
34. Wan B, Nie H, Liu A. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006; 177: 8844-8850.